Skip to main content
RDHL
NASDAQ Life Sciences

RedHill Biopharma Closes $6M Private Placement with Warrants, Securing Critical Liquidity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.801
Mkt Cap
$4.225M
52W Low
$0.71
52W High
$3.31
52W Position info
13% above low
Off High info
76% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

RDHL is trading near its 52-week low of $0.71 (13% above the low).

Summary

RedHill Biopharma announced the closing of its private placement, raising $6 million upfront with potential for an additional $13.4 million from warrant exercises, providing crucial liquidity for the company.


Key Events · Financing and Capital Events · RDHL

  • Private Placement Closed

    The company closed its previously announced private placement, receiving approximately $6 million in upfront gross proceeds.

  • Potential Additional Funding

    The offering includes Series A-1 and A-2 warrants, which, if fully exercised, could generate an additional $13.4 million in gross proceeds.

  • Strategic Use of Proceeds

    Proceeds are expected to strengthen near-term liquidity and support a potential transformative acquisition of commercial-stage, revenue-generating pharmaceutical product assets.

  • Dilutive Terms

    The ADSs and accompanying warrants were sold at a combined purchase price of $0.70 per ADS, a discount to the current market price, with warrant exercise prices at $0.86 and $0.70 per ADS.


Analysis · RDHL · Life Sciences

RedHill Biopharma has finalized a private placement, securing $6 million in upfront gross proceeds and potentially an additional $13.4 million from warrant exercises. This capital infusion is critical for the company, which recently received a Nasdaq delisting notice and disclosed substantial doubt about its ability to continue as a going concern. While the offering is highly dilutive at a discount to the current market price, it provides essential liquidity and is intended to support a potential transformative acquisition of revenue-generating assets, offering a lifeline for the company's immediate future.

At the time of this filing, RDHL was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDHL - Latest Insights

RDHL
Jul 28, 2026, 7:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.640
Real-time Price: $0.6097 info
Change: -$0.0303 (-5%) info
Market Cap: $4.074M info
RDHL
Jul 14, 2026, 6:00 AM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.690
Real-time Price: $0.6097 info
Change: -$0.0803 (-12%) info
Market Cap: $4.074M info
RDHL
Jul 02, 2026, 7:32 AM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $0.735744
Real-time Price: $0.6097 info
Change: -$0.126044 (-17%) info
Market Cap: $4.074M info
RDHL
Jun 29, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.860
Real-time Price: $0.6097 info
Change: -$0.2503 (-29%) info
Market Cap: $4.074M info
RDHL
Jun 29, 2026, 7:00 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $0.860
Real-time Price: $0.6097 info
Change: -$0.2503 (-29%) info
Market Cap: $4.074M info